English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Limited options are available for the treatment of pain in cats. Monoclonal antibodies ( mA bs) that neutralize nerve growth factor ( NGF ) have demonstrated analgesic capacity in rodent models, people with osteoarthritis, and dogs with degenerative joint disease.    Hypothesis/Objectives  This study describes the design and characterization of a fully felinized anti‐ NGF  monoclonal antibody. In vitro potency, pharmacokinetics, and the ability of the antibody to treat pain in a self‐resolving, acute inflammation model were investigated in cats.    Animals  Thirty‐eight cats at a research colony at Charles River Laboratories, Ireland.    Methods  Felinized anti‐ NGF mA b,  NV ‐02, was produced using a complementary  DNA  ( cDNA )‐based method ( PET ization). Purified  NV ‐02 was tested for affinity, potency, and immunoreactivity in vitro, then for safety and plasma pharmacokinetic distribution in vivo, and analgesic efficacy in a model of kaolin‐induced inflammatory pain.    Results  Anti‐NGF mAb,  NV ‐02 neutralized  NGF  with high affinity and potency and did not bind complement.  NV ‐02‐administered  SC  had a plasma half‐life of 7–15 days and was well tolerated at dosages up to 28 mg/kg. A dosage of 2 mg/kg  NV ‐02  SC  significantly decreased signs of lameness on day 2 ( P  = .0027), day 3 ( P  = .016), day 4, ( P  = .0063), day 5 ( P  = .0085), day 6 ( P  = .0014), and day 7 ( P  = .0034) after induction of inflammation.    Conclusions and Clinical Importance  The high affinity, long plasma half‐life, safety, and analgesic efficacy of felinized anti‐ NGF mA b ( NV ‐02) support further investigation of the analgesic potential of this antibody in the cat.

In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti‐Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats